Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2020

01-01-2020 | Prostate Cancer | Editorial

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer

Author: Gary J. R. Cook

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2020

Login to get access

Excerpt

With a propensity for prostate cancer to spread to the skeleton and the recognised shortcomings of conventional imaging, such as computed tomography (CT) and bone scintigraphy (BS) in detecting skeletal metastases, there is a need for more sensitive detection of bone metastases, both at diagnosis and at biochemical recurrence (BCR). The need for more sensitive imaging is now of greater importance with the introduction of several novel therapeutics for metastatic prostate cancer that can improve morbidity and prolong survival, as well as the introduction of potentially curative treatment strategies for those with oligometastatic disease. …
Literature
1.
Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, et al. The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE Trial. J Urol. 2019;201:322–31.CrossRef
2.
Teoh EJ, Bottomley D, Scarsbrook A, Payne H, Afaq A, Bomanji J, et al. The FALCON trial: impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging Res. 2018;8(Supp 1):5.
3.
Schuster DM, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y, et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014;55:1986–92.CrossRef
4.
Oka S, Kanagawa M, Doi Y, Schuster DM, Goodman MM, Yoshimura H. PET tracer (18)F-fluciclovine can detect histologically proven bone metastatic lesions: a preclinical study in rat osteolytic and osteoblastic bone metastasis models. Theranostics. 2017;7:2048–64.CrossRef
5.
Chen B, Wei P, Macapinlac HA, Lu Y. Comparison of 18F-fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Nucl Med Commun. 2019;40:940–6.CrossRef
6.
7.
Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, et al. Metabolic imaging of prostate cancer reveals intrapatient intermetastasis response heterogeneity to systemic therapy. Eur Urol Focus. 2017;3:639–42.CrossRef
8.
Messiou C, Cook G, Reid AH, Attard G, Dearnaley D, de Bono JS, et al. The CT flare response of metastatic bone disease in prostate cancer. Acta Radiol. 2011;52:557–61.CrossRef
9.
Israel O, Goldberg A, Nachtigal A, Militianu D, Bar-Shalom R, Keidar Z, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging. 2006;33:1280–4.CrossRef
10.
Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010;12:98–107.CrossRef
Metadata
Title
Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer
Author
Gary J. R. Cook
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04540-z

Other articles of this Issue 1/2020

European Journal of Nuclear Medicine and Molecular Imaging 1/2020 Go to the issue

Original Article

First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer

Letter to the Editor

Fitting of late dynamic [18F]MK6240 PET scans for in vivo tau quantification

Original Article

A combined analysis of maximum standardized uptake value on FDG-PET, genetic markers, and clinicopathological risk factors in the prognostic stratification of patients with resected oral cavity squamous cell carcinoma

Original Article

Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer

Image of the Month

An uncommon presentation of diffuse large B cell lymphoma with multiple peripheral nerve involvement demonstrated BY 18F-FDG PET/CT

Correction

Correction to: 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors